These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 20923685)

  • 21. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors.
    Rossi D; Sozzi E; Puma A; De Paoli L; Rasi S; Spina V; Gozzetti A; Tassi M; Cencini E; Raspadori D; Pinto V; Bertoni F; Gattei V; Lauria F; Gaidano G; Forconi F
    Br J Haematol; 2009 Jun; 146(1):64-75. PubMed ID: 19438485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of VH genes mutation status for prognosis of CLL patients.
    Bilous N; Abramenko I; Kryachok I; Bazyka D; Chumak A; Bebeshko V
    Exp Oncol; 2005 Dec; 27(4):325-9. PubMed ID: 16404355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features.
    Bomben R; Dal-Bo M; Benedetti D; Capello D; Forconi F; Marconi D; Bertoni F; Maffei R; Laurenti L; Rossi D; Del Principe MI; Luciano F; Sozzi E; Cattarossi I; Zucchetto A; Rossi FM; Bulian P; Zucca E; Nicoloso MS; Degan M; Marasca R; Efremov DG; Del Poeta G; Gaidano G; Gattei V
    Clin Cancer Res; 2010 Jan; 16(2):620-8. PubMed ID: 20068100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of gene expression signatures for molecular classification in human leukemia cells.
    Song JH; Kim HJ; Lee CH; Kim SJ; Hwang SY; Kim TS
    Int J Oncol; 2006 Jul; 29(1):57-64. PubMed ID: 16773185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.
    Abramenko I; Bilous N; Kryachok I; Filonenko I; Pilipenko G; Chumak A; Bazyka D; Bebeshko V
    Exp Oncol; 2007 Sep; 29(3):226-30. PubMed ID: 18004251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance.
    Zucchetto A; Sonego P; Degan M; Bomben R; Dal Bo M; Bulian P; Benedetti D; Rupolo M; Del Poeta G; Campanini R; Gattei V
    J Transl Med; 2006 Mar; 4():11. PubMed ID: 16509989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNA-based markers as prognostic factors in chronic lymphocytic leukemia.
    Sevov M; Rosenquist R; Mansouri L
    Expert Rev Hematol; 2012 Feb; 5(1):69-79. PubMed ID: 22272707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next generation RNA-sequencing in prognostic subsets of chronic lymphocytic leukemia.
    Mansouri L; Gunnarsson R; Sutton LA; Ameur A; Hooper SD; Mayrhofer M; Juliusson G; Isaksson A; Gyllensten U; Rosenquist R
    Am J Hematol; 2012 Jul; 87(7):737-40. PubMed ID: 22674506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia.
    Shehata M; Demirtas D; Schnabl S; Hilgarth M; Hubmann R; Fonatsch C; Schwarzinger I; Hopfinger G; Eigenberger K; Heintel D; Porpaczy E; Vanura K; Hauswirth A; Schwarzmeier JD; Gaiger A; Stilgenbauer S; Hallek M; Bilban M; Jäger U
    Leukemia; 2010 Dec; 24(12):2122-7. PubMed ID: 20966934
    [No Abstract]   [Full Text] [Related]  

  • 30. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia.
    Herold T; Jurinovic V; Metzeler KH; Boulesteix AL; Bergmann M; Seiler T; Mulaw M; Thoene S; Dufour A; Pasalic Z; Schmidberger M; Schmidt M; Schneider S; Kakadia PM; Feuring-Buske M; Braess J; Spiekermann K; Mansmann U; Hiddemann W; Buske C; Bohlander SK
    Leukemia; 2011 Oct; 25(10):1639-45. PubMed ID: 21625232
    [No Abstract]   [Full Text] [Related]  

  • 31. CCR7 in Blood Cancers - Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target.
    Cuesta-Mateos C; Terrón F; Herling M
    Front Oncol; 2021; 11():736758. PubMed ID: 34778050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-Factor Clustering Incorporating Cell Motility Predicts T Cell Expansion Potential.
    Lee JH; Shao S; Kim M; Fernandes SM; Brown JR; Kam LC
    Front Cell Dev Biol; 2021; 9():648925. PubMed ID: 33898440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.
    Cuesta-Mateos C; Brown JR; Terrón F; Muñoz-Calleja C
    Front Immunol; 2021; 12():662866. PubMed ID: 33841445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiparametric analysis of CD8
    Gonnord P; Costa M; Abreu A; Peres M; Ysebaert L; Gadat S; Valitutti S
    Oncoimmunology; 2019; 8(4):e1570774. PubMed ID: 30906665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated machine learning pipeline for aberrant biomarker enrichment (i-mAB): characterizing clusters of differentiation within a compendium of systemic lupus erythematosus patients.
    Le TT; Blackwood NO; Taroni JN; Fu W; Breitenstein MK
    AMIA Annu Symp Proc; 2018; 2018():1358-1367. PubMed ID: 30815180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SLAMF6 in health and disease: Implications for therapeutic targeting.
    Yigit B; Wang N; Herzog RW; Terhorst C
    Clin Immunol; 2019 Jul; 204():3-13. PubMed ID: 30366106
    [No Abstract]   [Full Text] [Related]  

  • 37. The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.
    Gordiienko I; Shlapatska L; Kholodniuk V; Sklyarenko L; Gluzman DF; Clark EA; Sidorenko SP
    PLoS One; 2017; 12(10):e0185940. PubMed ID: 28982149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells.
    Yigit B; Halibozek PJ; Chen SS; O'Keeffe MS; Arnason J; Avigan D; Gattei V; Bhan A; Cen O; Longnecker R; Chiorazzi N; Wang N; Engel P; Terhorst C
    Oncotarget; 2016 May; 7(18):26346-60. PubMed ID: 27029059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting of Ly9 (CD229) Disrupts Marginal Zone and B1 B Cell Homeostasis and Antibody Responses.
    Cuenca M; Romero X; Sintes J; Terhorst C; Engel P
    J Immunol; 2016 Jan; 196(2):726-37. PubMed ID: 26667173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.
    Bologna C; Buonincontri R; Serra S; Vaisitti T; Audrito V; Brusa D; Pagnani A; Coscia M; D'Arena G; Mereu E; Piva R; Furman RR; Rossi D; Gaidano G; Terhorst C; Deaglio S
    J Clin Invest; 2016 Jan; 126(1):181-94. PubMed ID: 26619119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.